<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03045471</url>
  </required_header>
  <id_info>
    <org_study_id>ARL-1</org_study_id>
    <nct_id>NCT03045471</nct_id>
  </id_info>
  <brief_title>The Efficacy and Safety of R-EPOCH and R-CHOP Regimen for Patients With AIDS Associated CD20+ Diffuse Large B Lymphoma</brief_title>
  <official_title>The Efficacy and Safety of R-EPOCH and R-CHOP Regimen for Patients With AIDS Associated CD20+ Diffuse Large B Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai Public Health Clinical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shanghai Public Health Clinical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      1. Compare the efficacy of R-EPOCH and R-CHOP regimen for patients with AIDS associated CD20+
      diffuse large B lymphoma; 2. Compare the safety of R-EPOCH and R-CHOP regimen for patients
      with AIDS associated CD20+ diffuse large B lymphoma.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">March 1, 2017</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>progression-free survival</measure>
    <time_frame>3 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>complete response rate</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>partial response partial response rate</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>overall response</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">50</enrollment>
  <condition>To Evaluate the Efficacy and Safety of R-EPOCH and R-CHOP Regimen for Patients With AIDS Associated CD20+ Diffuse Large B Lymphoma</condition>
  <arm_group>
    <arm_group_label>R-EPOCH</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>R-CHOP</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>R-EPOCH</intervention_name>
    <description>Rituximab: an anti-CD20 monoclonal antibody, which has the ability to kill B cells, be they normal or malignant; Etoposide: a topoisomerase inhibitor from the group of epipodofyllotoxins; Prednisolone: a glucocorticoid hormone that can cause apoptosis and lysis of both normal and malignant lymphocytes; Oncovin, also known as vincristine: a vinca alkaloid that binds to the protein tubulin, thereby preventing the formation of microtubules and mitosis; Cyclophosphamide: an alkylating antineoplastic agent; Hydroxydaunorubicin, also known as doxorubicin: an anthracycline antibiotic that is able to intercalate DNA, damaging it and preventing the cell division.</description>
    <arm_group_label>R-EPOCH</arm_group_label>
    <other_name>Rituximab,Etoposide,Prednisolone,Oncovin,Cyclophosphamide,Hydroxydaunorubici</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>R-CHOP</intervention_name>
    <description>Rituximab: an anti-CD20 monoclonal antibody, which has the ability to kill B cells, be they normal or malignant; Prednisolone: a glucocorticoid hormone that can cause apoptosis and lysis of both normal and malignant lymphocytes; Oncovin, also known as vincristine: a vinca alkaloid that binds to the protein tubulin, thereby preventing the formation of microtubules and mitosis; Cyclophosphamide: an alkylating antineoplastic agent; Hydroxydaunorubicin, also known as doxorubicin: an anthracycline antibiotic that is able to intercalate DNA, damaging it and preventing the cell division.</description>
    <arm_group_label>R-CHOP</arm_group_label>
    <other_name>Rituximab,Prednisolone,Oncovin,Cyclophosphamide,Hydroxydaunorubici</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with AIDS associated CD20+ diffuse large B lymphoma
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. male or female aged 18-60 years old;

          2. Confirmed as AIDS patients and treated with HAART;

          3. Confirmed as CD20+ diffuse large B lymphoma;

          4. Serum test; negative for HBV, HCV and syphilis;

          5. Hematology: Absolute neutrophil count greater than or equal to 1000/mm(3); Platelet
             count greater than or equal to 50,000/mm(3); Hemoglobin greater than 8.0 g/dl;
             Lymphocyte count less than or equal to 4,000/mm(3);

          6. Chemistry: Serum ALT/AST less or equal to 5 times the upper limit of normal. Serum
             creatinine less than or equal to 1.6 mg/dl. Total bilirubin less than or equal to 1.5
             mg/dl;

          7. Normal cardiac ejection fraction and no evidence of pericardial effusion as determined
             by an echocardiogram;

          8. Negative pregnancy test for female;

          9. Patients of both genders must be willing to practice birth control from the time of
             enrollment on this study and for four months after treatment;

         10. To be able to understand and sign the Informed Consent Document with legal force.

        Exclusion Criteria:

          1. With acute disease, active infection, hemolytic anemia, coagulation dysfunction or
             diseases of the respiratory, circulation or central nervous system;

          2. Patients with heart metastases, CNS metastases or cerebrospinal fluid malignant cells;

          3. Women with pregnant or breastfeeding;

          4. Any form of primary immunodeficiency;

          5. Concurrent Systemic steroid therapy;

          6. History of severe immediate hypersensitivity reaction to any of the agents used in
             this study;

          7. History of allogeneic stem cell transplantation.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Hongzhou Lu, PhD</last_name>
    <phone>+8618930810088</phone>
    <email>luhongzhou@fudan.edu.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Renfang Zhang, Msc</last_name>
    <phone>+8618916051096</phone>
    <email>zhangrenfang@shaphc.org</email>
  </overall_contact_backup>
  <verification_date>February 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 3, 2017</study_first_submitted>
  <study_first_submitted_qc>February 6, 2017</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 7, 2017</study_first_posted>
  <last_update_submitted>February 6, 2017</last_update_submitted>
  <last_update_submitted_qc>February 6, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 7, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Shanghai Public Health Clinical Center</investigator_affiliation>
    <investigator_full_name>Hongzhou Lu</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Rituximab</mesh_term>
    <mesh_term>Antineoplastic Agents, Alkylating</mesh_term>
    <mesh_term>Etoposide</mesh_term>
    <mesh_term>Prednisolone</mesh_term>
    <mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
    <mesh_term>Antineoplastic Agents</mesh_term>
    <mesh_term>Vincristine</mesh_term>
    <mesh_term>Prednisolone acetate</mesh_term>
    <mesh_term>Methylprednisolone acetate</mesh_term>
    <mesh_term>Methylprednisolone</mesh_term>
    <mesh_term>Prednisolone hemisuccinate</mesh_term>
    <mesh_term>Prednisolone phosphate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

